Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and …
用户zXqBMD2rfL_4
3个月前
90
10
已关闭
DOI:
文献链接:
其他信息:
T Grote, J Hajdenberg, A Cartmell…
The journal of …, 2006
europepmc.org
The objective of this multicenter, phase II, open-label study was to evaluate the safety and efficacy of the newest 5-hydroxytryptamine3 (5-HT3) receptor antagonist, palonosetron, plus dexamethasone and aprepitant in preventing nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eligible patients received a single intravenous dose of palonosetron (0.25 mg on day 1 of chemotherapy), along with 3 daily oral doses of aprepitant (125 mg on day 1, 80 mg on days 2 and 3) and dexamethasone (12 mg on day 1 …
